Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 1996

View Archived Issues

Therapeutically active nicotinic acid esters described by Scotia

Bayer describes new ASA derivatives

New lipophilic drug delivery agents from Scotia

Radiopharmaceutical agents from CIS Bio International

Mercian reports new antitumor anthracycline

Antineoplastic anthracycline antibiotic disclosed by Mercian

Innapharma reports novel antidepressant

DuPont Merck developing atypical antipsychotic

DuPont Merck reports ester prodrugs for glaucoma

NK1 receptor antagonist synthesized by RPR

5-LO inhibitor under evaluation at SKB

HemispheRx and Temple University enter new agreement for Oragen products

MedImmune receives patent coverage for RespiGam

Antex to be issued patent covering H. influenzae proteins

Prostate cancer gene therapy trial commences

The role of host factors in HIV pathogenesis

Innovative NRT recommended for approval

New insights into migraine pathology

Carrington Laboratories and Recordati reach licensing agreement

Positive phase II results with RMP-7/carboplatin

Clinical trial on OXiGENE's Sensamide/Neu-Sensamide nearing completion

Medtronic and Orphan Medical to develop intrathecal clonidine

Circularly permuted proteins and fusion proteins available for licensing

Licensees sought for vector for polynucleotide vaccines

Heterologous vectors for boosting antitumor immunity available for licensing

Licenses offered for marker in the human iNOS gene promoter region

Knoll licenses technology for use in cardiovascular research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...